Brokerages forecast that NeoGenomics, Inc. (NASDAQ:NEO) will report $0.04 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for NeoGenomics’ earnings. The lowest EPS estimate is $0.03 and the highest is $0.07. NeoGenomics reported earnings of $0.05 per share during the same quarter last year, which would suggest a negative year over year growth rate of 20%. The firm is expected to issue its next quarterly earnings report on Wednesday, February 28th.

According to Zacks, analysts expect that NeoGenomics will report full-year earnings of $0.15 per share for the current financial year, with EPS estimates ranging from $0.11 to $0.21. For the next fiscal year, analysts anticipate that the company will post earnings of $0.24 per share, with EPS estimates ranging from $0.17 to $0.32. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow NeoGenomics.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Wednesday, October 25th. The medical research company reported $0.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.01. The firm had revenue of $63.05 million for the quarter, compared to the consensus estimate of $63.11 million. NeoGenomics had a negative net margin of 4.78% and a positive return on equity of 3.98%. The business’s revenue was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.04 earnings per share.

A number of analysts have recently issued reports on the company. Janney Montgomery Scott reissued a “buy” rating on shares of NeoGenomics in a research report on Thursday, October 26th. Zacks Investment Research lowered NeoGenomics from a “hold” rating to a “sell” rating in a research report on Thursday, October 5th. BidaskClub lowered NeoGenomics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 13th. Gabelli assumed coverage on NeoGenomics in a research report on Thursday, August 24th. They set a “buy” rating and a $9.00 price target on the stock. Finally, BTIG Research reissued a “hold” rating on shares of NeoGenomics in a research report on Sunday, October 29th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. NeoGenomics has a consensus rating of “Hold” and a consensus price target of $10.33.

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of NeoGenomics by 1.7% in the second quarter. Vanguard Group Inc. now owns 2,724,603 shares of the medical research company’s stock worth $24,413,000 after purchasing an additional 44,820 shares in the last quarter. First Light Asset Management LLC lifted its holdings in shares of NeoGenomics by 1.0% in the second quarter. First Light Asset Management LLC now owns 2,679,271 shares of the medical research company’s stock valued at $24,006,000 after buying an additional 25,617 shares during the period. Janus Henderson Group PLC acquired a new stake in shares of NeoGenomics in the second quarter valued at $20,651,000. Russell Investments Group Ltd. lifted its holdings in shares of NeoGenomics by 66.1% in the second quarter. Russell Investments Group Ltd. now owns 1,996,710 shares of the medical research company’s stock valued at $17,891,000 after buying an additional 794,281 shares during the period. Finally, Granite Investment Partners LLC lifted its holdings in shares of NeoGenomics by 52.4% in the second quarter. Granite Investment Partners LLC now owns 1,976,020 shares of the medical research company’s stock valued at $17,706,000 after buying an additional 679,778 shares during the period. 79.74% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “NeoGenomics, Inc. (NEO) Expected to Post Earnings of $0.04 Per Share” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/11/03/neogenomics-inc-neo-expected-to-post-earnings-of-0-04-per-share.html.

About NeoGenomics

NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.

Get a free copy of the Zacks research report on NeoGenomics (NEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.